Imunon
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
997 Lenox Dr Ste 100, Lawrenceville, New...Phone Number
(609) 896-9100Website
www.imunon.comRevenue
-Stock Symbol
IMNNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Imunon
Imunon is a clinical-stage biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines that work in harmony with the bodys immune system. The company leverages proprietary non-viral nucleic acid delivery platforms to create treatments for challenging cancers and infectious diseases, with a strong emphasis on harnessing natural biological mechanisms to generate durable therapeutic responses. Through its integrated research, development, and manufacturing capabilities, Imunon advances novel immunology-driven medicines designed to address unmet medical needs and improve patient outcomes across a broad range of serious health conditions.Explore more
Imunon Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imunon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Imunon launches new products
Imunon, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Imunon is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Imunon
Earning: See what the market has to say on Imunon recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Imunon had a recent Job posting/layoffs
Check if Imunon has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Imunon has new funding data
Recommended Actions
Reach out to Masked Content who joined Imunon as Masked Content
Find more new buyers
Compare Similar Companies to Imunon
Compare insights from companies similar to Imunon, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Imunon is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Imunon is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Imunon.
Imunon financials insights
Gather financial insights about Imunon, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$10M
Imunon Tech Stack
A closer look at the technologies used by Imunon
Most Recent Scoops
Project
Imunon is currently enrolling patients in OVATION 3, its pivotal Phase III trial evaluating IMNN-001 in combination with standard-of-care chemotherapy in newly diagnosed advanced epithelial ovarian cancer patients, at a rate of approximately 0.5 patients per site per month, exceeding the trial plan assumption of 0.3 patients per site per month and the historical ovarian cancer study rate of approximately 0.2 patients per site per month.
Clinical Operations
Earnings
Imunon has reported general and administrative expenses of $1.3 million for Q2, down approximately 20% compared with $1.6 million in the prior year period, reflecting the company's ongoing cost containment initiatives.
Spending/Investment, Finance, Financial Operations
Earnings
Imunon has reported net cash used for operating activities of $3.0 million for Q2 of 2026, down from $4.0 million used in Q1 of 2026.
Earnings, Finance, Financial Operations
Earnings
Imunon has reported research and development expenses of $1.5 million for Q2, compared with $1.2 million for the same period last year, primarily reflecting higher clinical and manufacturing costs related to the OVATION 3 study.
Earnings, Research & Development, Finance
Project
Pharmaceuticals, Clinical Operations
Imunon News & Media
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ETIMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestonesIMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancerIMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
LAWRENCEVILLE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, August 11, 2026 to discuss financial results for the second quarter ended June 30, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing Ph
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Imunon
Sign Up For FreeTo access detailed company insights
Imunon is a clinical-stage biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines that work in harmony with the bodys immune system. The company leverages proprietary non-viral nucleic acid delivery platforms to create treatments for challenging cancers and infectious diseases, with a strong emphasis on harnes... Read More
